Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter phase 3 trial of naldemedine for opioid-induced constipation in cancer patients
ChiCTR2400089290Phase 3Completed
- Sponsor
- The Second Affiliated Hospital of Anhui Medical University
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in opioid-induced constipation (OIC) comparing Naldemedine arm with Placebo arm (2 arms). Primary endpoint: Proportion of SBM responders during Period 1 of the Treatment Period. Started Sep 2024; status: completed.
02
Drugs
naldemedine
03
Conditions
opioid-induced constipation (OIC)
Beyond the preview
Go deeper on ChiCTR2400089290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089290.